|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
One (1.6%) cancer tissue sample showed a point mutation in the BRAF gene (GTG --> GAG; V599E).
|
15616773 |
2004 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Elucidating the spectrum of non-p. V600E BRAF mutations in different malignancies is a first step toward understanding their clinical significance.
|
26386083 |
2015 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The aim of the correlative tumour tissue studies was to investigate the relationship between EGFR gene copy numbers, activation of the EGFR pathway, expression and mutation of E-cadherin, V600E BRAF mutation and clinical outcome of patients with gastric and OGJ cancer treated with cetuximab combined with FUFOX.
|
22152101 |
2011 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Detection of the BRAF V600E mutation is therefore a useful adjunct in the differential diagnosis of HCL and HCL variant and highlights the value of a multifaceted approach to the diagnosis of this malignancy.
|
22313586 |
2012 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Approximately 75% of the cases were cytologically diagnosed as being positive for malignancy and these cases were associated with both the classic and tall cell variants of PTC at the time of resection, a greater likelihood of extrathyroidal extension, and the V600E type of BRAF mutation.
|
22887810 |
2013 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Two of 5 patients with BRAF V600E had progression, including 1 GT-UMP with local recurrence and 1 malignant tumor with enlarging residual disease.
|
28834810 |
2017 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
These data demonstrate that clonal BRAF(V600E) is a rare occurrence in PTC, although frequently this cancer consists of a mixture of tumor cells with wild-type and mutant BRAF.
|
22170714 |
2012 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our findings provide evidence of critical survival signals in BRAF non-V600E mutant c</span>ancers, which could pave the way for effective treatment of these cancers.
|
29348459 |
2018 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Interesting, Prof. Peng Hou and colleagues, at the First Affiliated Hospital of Xi'an Jiaotong University in China, identified unknown epigenetic mechanisms and their involvement in the tumorigenesis of B-RAF(V600E)-driven cancer.
|
28638488 |
2017 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Braf(V600E)-driven tumors require autophagy and likely autophagy-provided substrates to maintain mitochondrial metabolism and to promote tumor growth, suggesting that autophagy ablation may improve cancer therapy.
|
24860158 |
2014 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Furthermore, RAS function is not required for the growth of cancer cell lines with the V599E mutation.
|
12068308 |
2002 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Thyroid-specific deletion of the Gsα gene in LSL-Braf(V600E)/TPO-Cre/Gnas-E1(fl/fl) mice also resulted in an attenuated cancer phenotype, indicating that the cooperation of TshR with oncogenic Braf is mediated in part by cAMP signaling.
|
21220306 |
2011 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
We found that gene mutations for EGFR (P = .02) and ALK (P < .001) were associated with cancer diagnosis at a younger age, and a similar trend existed for ERBB2 (P = .15) and ROS1 (P = .10) but not BRAF V600E (P = .43).
|
26720421 |
2016 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Activating B-RAF(V600E) (also known as BRAF) kinase mutations occur in ∼7% of human malignancies and ∼60% of melanomas.
|
21107323 |
2010 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The frequency of malignancy and the BRAF(V600E) mutation were compared between suspicious and probably benign nodules on US and between groups 1 and 2.
|
20945104 |
2011 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The aims of this study were to evaluate the utility of US-guided FNAB in the diagnostic assessment of nodules with or without clinical/US features suggestive for malignancy and to investigate the additional contribution of BRAF V600E mutation analysis in the detection of differentiated thyroid cancer.
|
22535974 |
2012 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Papillary thyroid cancer subjects harboring RET/PTC rearrangements developed this cancer earlier than did cases with BRAF(V600E) mutation (P = 0.03).
|
18757433 |
2008 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF (V600E) mutation was found in about one in two nodules with thyroid FNA read as SFM, its PPV to detect cancers was excellent, and its NPV was very poor.
|
31811566 |
2020 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Reverse Phase Proteomic Array (RPPA, MD Anderson Cell Lines Project), RNAseq (Cancer Cell Line Encyclopedia) and vemurafenib sensitivity (Cancer Therapeutic Response Portal) data for BRAF-V600E cancer cell lines were curated.
|
31672130 |
2019 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
PGC1α-negative papillary cancer was associated with BRAF V600E mutation, large tumor size, extrathyroidal or lymphovascular invasion, lymph node metastasis, and advanced stage.
|
31333799 |
2019 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
For the 37 cases cytologists favored to be cPTC, 31 (84%) had a molecular result that supported malignancy (28 BRAF V600E mutations, 2 NTRK1 fusions, 1 AGK-BRAF fusion).
|
29396809 |
2018 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our finding of tumor-specific patterns of NR expression, as well as significant differences in NR expression between BRAF(V600E) and wild type BRAF PTC, provides a basis for further mechanistic studies and highlights potential novel therapeutic targets for this malignancy.
|
24559275 |
2014 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The V600E mutation accounts for most of the BRAF mutations in cancer, and KRAS mutations are predominantly encoded by nucleotide substitutions within codons 12 and 13.
|
19430299 |
2009 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
We calculated and compared the diagnostic performances of cytology and cytology with BRAF(V600E) mutation analysis to detect malignancy among thyroid nodules according to ultrasound features and size.
|
23717622 |
2013 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Furthermore, when we introduce the equivalent of the most common cancer mutation in B-RAF (V600E) into C-RAF, it only has a weak effect on kinase activity and does not convert C-RAF into an oncogene.
|
16266992 |
2005 |